PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19597528-9 2009 The angiotensin AT1 receptor antagonist losartan blocked the effects of ADT-induced cell proliferation, TGF-beta1 and collagen type IV synthesis and secretion. Losartan 40-48 transforming growth factor, beta 1 Rattus norvegicus 104-113 19652382-4 2009 Losartan treatment also down-regulated transforming growth factor-beta1 expression and attenuated the increased expression levels of p22(phox) and Nox4. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 39-71 18812657-9 2008 Losartan reduced KW/BW, urinary TXB2, and 24 h urinary protein counts and significantly suppressed the over-expression of COX2 and TGF-beta1. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 131-140 18631342-4 2008 Pirfenidone and losartan reduce TGF-beta expression and decrease postinflammatory fibrosis in the lungs, kidneys, heart and liver. Losartan 16-24 transforming growth factor, beta 1 Rattus norvegicus 32-40 18812657-11 2008 Losartan could suppress the expression of COX2 and TGF-beta1 in the kidney of DN rats and attenuate the renal lesions caused by DN. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 51-60 18812664-5 2008 RESULTS: Blood urea nitrogen, GSI and the expressions of collagen Type IV and CTGF protein in the losartan group were lower than those in the model group(all P<0.05), and the expressions of collagen Type IV mRNA,TGF-beta1 mRNA and CTGF mRNA were lower than those in the model group (all P<0.05). Losartan 98-106 transforming growth factor, beta 1 Rattus norvegicus 215-224 18812664-6 2008 CONCLUSION: Losartan modulates glomerular sclerosis and decreases the accumulation of collagen Type IV by inhibiting TGF-beta1 and CTGF. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 117-126 17784886-7 2007 In addition, TGFbeta1 levels were significantly elevated in high-dose losartan-treated rats (P < 0.01). Losartan 70-78 transforming growth factor, beta 1 Rattus norvegicus 13-21 18457832-5 2008 Benidipine and losartan also reduced the aortic expression of transforming growth factor-beta1 mRNA and thickening of the vascular wall to a similar extent. Losartan 15-23 transforming growth factor, beta 1 Rattus norvegicus 62-94 18182718-0 2007 [Effect of losartan on the expressions of TGF-beta1, p-Smad2/3, and Smad7 in the remnant renal tissues of 5/6 nephrectomized rats]. Losartan 11-19 transforming growth factor, beta 1 Rattus norvegicus 42-51 18182718-1 2007 OBJECTIVE: To investigate the mechanism of losartan treating glomerulosclerosis and to observe the effect of losartan on the expressions of TGF-beta1, p-Smad2/3, and Smad7 in the renal tissues of 5/6 nephrectomized rats. Losartan 109-117 transforming growth factor, beta 1 Rattus norvegicus 140-149 18182718-8 2007 The expressions of TGF-beta1 and p-Smad2/3 were just at a low level in the renal tissues of the rats in the sham-operated group, and were strongly positive in the model group; but losartan could decrease the expressions of TGF-beta1 and p-Smad2/3 (P<0.01). Losartan 180-188 transforming growth factor, beta 1 Rattus norvegicus 19-28 18182718-8 2007 The expressions of TGF-beta1 and p-Smad2/3 were just at a low level in the renal tissues of the rats in the sham-operated group, and were strongly positive in the model group; but losartan could decrease the expressions of TGF-beta1 and p-Smad2/3 (P<0.01). Losartan 180-188 transforming growth factor, beta 1 Rattus norvegicus 223-232 18182718-10 2007 CONCLUSION: Losartan may implement its anti-glomerulosclerosis by affecting TGF-beta1, p-Smad2/3, and Smad7 of TGF-beta/Smads pathway of the renal tissues of 5/6 nephrectomized rats. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 76-85 18182718-10 2007 CONCLUSION: Losartan may implement its anti-glomerulosclerosis by affecting TGF-beta1, p-Smad2/3, and Smad7 of TGF-beta/Smads pathway of the renal tissues of 5/6 nephrectomized rats. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 76-84 18583228-8 2008 RESULTS: Both perindopril and losartan treatment significantly reduced the pulmonary fibrosis score, content of hydroxyproline, protein expression of TGF-beta1, DNA binding activity of NF-kappaB and MMP-2, 9 activity, and increased cytoplasmic protein expression of IkappaBalpha. Losartan 30-38 transforming growth factor, beta 1 Rattus norvegicus 150-159 18583228-10 2008 CONCLUSION: Perindopril and losartan may inhibit bleomycin A5-induced pulmonary fibrosis in rats by reducing the protein expression of TGF-beta1 and suppressing the DNA binding activity of NF-kappaB and MMP-2, 9 activity. Losartan 28-36 transforming growth factor, beta 1 Rattus norvegicus 135-144 17784886-8 2007 CONCLUSION: These results show that losartan can induce apoptosis of prostate epithelium and increase the TGFbeta1 expression in SH rats, suggesting that Ang II stimulation might be involved in the pathogenesis of BPH, which might correlate with the regulation of TGFbeta1 expression. Losartan 36-44 transforming growth factor, beta 1 Rattus norvegicus 106-114 17784886-8 2007 CONCLUSION: These results show that losartan can induce apoptosis of prostate epithelium and increase the TGFbeta1 expression in SH rats, suggesting that Ang II stimulation might be involved in the pathogenesis of BPH, which might correlate with the regulation of TGFbeta1 expression. Losartan 36-44 transforming growth factor, beta 1 Rattus norvegicus 264-272 17206447-7 2007 Inhibition of the increase in cardiac TGF-beta1 levels was observed in the groups treated with T4 in association with losartan or PD123319 when compared to the T4 - 10 group. Losartan 118-126 transforming growth factor, beta 1 Rattus norvegicus 38-47 16309579-8 2005 Prevention of renal fibrogenesis by Losartan treatment was demonstrated by TGFbeta mRNA expression similar to control. Losartan 36-44 transforming growth factor, beta 1 Rattus norvegicus 75-82 16330873-14 2006 Serum TGF-beta1 levels of pulmonary fibrosis rats were also decreased by losartan. Losartan 73-81 transforming growth factor, beta 1 Rattus norvegicus 6-15 16330873-15 2006 CONCLUSIONS: Losartan had an inhibitory effect on bleomycin-induced pulmonary fibrosis, and its effect may be associated with its anti-free radicals and the reduction in TGF-beta1. Losartan 13-21 transforming growth factor, beta 1 Rattus norvegicus 170-179 16310163-10 2006 Moreover, Ang II induction of TSP1 and increased TGF-beta activity were blocked by losartan, an antagonist of the Ang II type 1 (AT1) receptor. Losartan 83-91 transforming growth factor, beta 1 Rattus norvegicus 49-57 16191423-7 2005 This study suggested that blocking RAS using Benazepril or Losartan can have protective effects on the renal injury in glomerulosclerosis by down-regulating the expressions of TGF-beta1, Col IV, Fn, ET-1 and iNOS. Losartan 59-67 transforming growth factor, beta 1 Rattus norvegicus 176-185 15637465-8 2005 CONCLUSION: Losartan is capable of abrogating the upregulation of TGF-beta1 and betaig-h3 expression, and this is associated with attenuated tubulointerstitial fibrosis in chronic CsA nephrotoxicity. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 66-75 12846751-12 2003 Overexpression of TGF beta 1 and VEGF was observed in the glomeruli of diabetic rats and was attenuated by losartan, simvastatin, or the combination of both to a similar level. Losartan 107-115 transforming growth factor, beta 1 Rattus norvegicus 18-28 15149322-7 2004 RESULTS: After administration of a nonhypotensive dose of losartan prevention of renal fibrogenesis was demonstrated in obstructed kidneys by means of Vv values and TGF-beta mRNA expression near controls. Losartan 58-66 transforming growth factor, beta 1 Rattus norvegicus 165-173 14599716-11 2003 On the other hand, angiotensin II stimulated mRNA expression of TGF-beta and fibronectin, which could be inhibitable by saralasin and losartan, the nonselective and specific antagonists for AT(1) receptors, respectively. Losartan 134-142 transforming growth factor, beta 1 Rattus norvegicus 64-72 15573910-11 2004 In in vitro experiments, losartan (1 x 10(-9) - 1 x 10(-5) M) significantly reduced TNF-alpha and TGF-beta1 levels in culture supernatants of KCs, but captopril (1 x 10(-5) M) did not. Losartan 25-33 transforming growth factor, beta 1 Rattus norvegicus 98-107 15573910-12 2004 The results showed that losartan significantly inhibited the progression of hepatic fibrosis induced by CCl4, and the inhibitory effect of losartan on hepatic fibrosis might be associated with its ability to inhibit the production of TNF-alpha and TGF-beta1 by activated KCs. Losartan 139-147 transforming growth factor, beta 1 Rattus norvegicus 248-257 12930639-15 2003 Both of perindopril and losartan treatment significantly reduced mean fibrosis score, messenger RNA and protein levels of AT1 receptor, protein levels of TGF-beta1 and PDGF-BB, Serum levels of HA and LN, and MMP-2 activity. Losartan 24-32 transforming growth factor, beta 1 Rattus norvegicus 154-163 12895325-1 2003 OBJECTIVE: To investigate the influence of losartan on the expression of transforming growth factor-beta type I and type II receptors (TGF beta RI, TGF beta RII) in kidney of diabetic rat model. Losartan 43-51 transforming growth factor, beta 1 Rattus norvegicus 135-143 12895325-1 2003 OBJECTIVE: To investigate the influence of losartan on the expression of transforming growth factor-beta type I and type II receptors (TGF beta RI, TGF beta RII) in kidney of diabetic rat model. Losartan 43-51 transforming growth factor, beta 1 Rattus norvegicus 148-156 12592643-11 2003 The urinary TGF-beta excretion (pg/mg urinary creatinine) was 48.6 +/- 5.9 in control animals, 603.9 +/- 80.41 in untreated diabetic rats, 279.3 +/- 47.0 in diabetic rats treated with enalapril, and 243.7 +/- 40.0 in rats treated with losartan. Losartan 235-243 transforming growth factor, beta 1 Rattus norvegicus 12-20 12592643-12 2003 CONCLUSIONS: We concluded that enalapril or losartan treatment can modify events that precede diabetic nephropathy by reducing TGF-beta and fibronectin expression in glomeruli and tubulointerstitium as well as urinary TGF-beta content. Losartan 44-52 transforming growth factor, beta 1 Rattus norvegicus 127-135 12592643-12 2003 CONCLUSIONS: We concluded that enalapril or losartan treatment can modify events that precede diabetic nephropathy by reducing TGF-beta and fibronectin expression in glomeruli and tubulointerstitium as well as urinary TGF-beta content. Losartan 44-52 transforming growth factor, beta 1 Rattus norvegicus 218-226 10512375-11 1999 Incubation of cells with 30 mmol/l glucose increased total TGF-beta1 secretion, which was also normalized by losartan. Losartan 109-117 transforming growth factor, beta 1 Rattus norvegicus 59-68 11025760-8 2000 The nitric oxide synthase inhibitor, N-nitro-L-arginine (L-NAME) or angiotensin II type I receptor blocker, losartan, inhibited nitric oxide and TGF-beta1 induced by angiotensin II. Losartan 108-116 transforming growth factor, beta 1 Rattus norvegicus 145-154 11518857-10 2001 However, losartan, but not the TRx, significantly attenuated the rise of serum creatinine, proteinuria and urinary ET-1 and TGF-beta1 excretion, as well as ET-1 content in glomeruli of uremic rats. Losartan 9-17 transforming growth factor, beta 1 Rattus norvegicus 124-133 11087260-3 2000 AT(1) blockade (losartan) attenuated the activation of TGF-beta(1) in target tissues. Losartan 16-24 transforming growth factor, beta 1 Rattus norvegicus 55-63 10505424-8 1999 Captopril or losartan treatment suppressed the acute induction of TGF-beta1 mRNA expressions. Losartan 13-21 transforming growth factor, beta 1 Rattus norvegicus 66-75 10681670-1 1999 The angiotensin II receptor 1 antagonist losartan (L) inhibited the advanced glycated end-products (AGEs) induced expression of transforming growth factor beta(1) in in vitro experiments performed on renal tubuloepithelial cells. Losartan 41-49 transforming growth factor, beta 1 Rattus norvegicus 128-162 9236148-10 1997 The AT1 receptor antagonist Losartan (10(-7) m) greatly attenuated Ang II-stimulated TGF-B1 secretion and decreased TGF-beta1 immunostaining in VIC. Losartan 28-36 transforming growth factor, beta 1 Rattus norvegicus 85-91 9737942-8 1998 We studied: (1) localization and expression of angiotensin converting enzyme (ACE), AngII receptors, TGF-beta1 mRNA and its receptors in the infarcted rat heart; and (2) effect of AngII on TGF-beta1 synthesis by chronic blockade of AT1 receptors began at the time of surgery by losartan in rats with MI. Losartan 278-286 transforming growth factor, beta 1 Rattus norvegicus 189-198 9261254-11 1997 Furthermore, angiotensin II (10(-6) mol/L) upregulated TGF-beta 1 mRNA levels fivefold in rat and fourfold in human VSMCs; this effect was prevented by losartan but not by PD123319. Losartan 152-160 transforming growth factor, beta 1 Rattus norvegicus 55-65 9844133-5 1998 RESULTS: Both enalapril and losartan reduced TGF-beta overproduction in a dose-dependent manner, showing a moderate reduction at doses known to control blood pressure in renal forms of hypertension. Losartan 28-36 transforming growth factor, beta 1 Rattus norvegicus 45-53 9844133-6 1998 A maximal reduction in TGF-beta expression of approximately 45% was seen for both drugs starting at 100 mg/liter enalapril and 500 mg/liter losartan, with no further reduction at doses of enalapril up to 1000 mg/liter or losartan up to 2500 mg/liter. Losartan 140-148 transforming growth factor, beta 1 Rattus norvegicus 23-31 9355076-4 1997 After subtotal renal ablation, rats fed a 40% protein diet and treated with losartan not only had a reduction in systolic BP (96 +/- 8 versus 130 +/- 8 mmHg, P < 0.05, losartan versus control) and urinary protein excretion (4 +/- 5 versus 23 +/- 20 g/d, P < 0.05, losartan versus control), but also exhibited a reduction in renal TGF-beta 1 mRNA (194 +/- 64 versus 411 +/- 101 optical density units, P < 0.05, losartan versus control) and TGF-beta 1 protein levels (9.8 +/- 2.5 versus 18.6 +/- 5.8 ng/g of renal tissue, P < 0.05, losartan versus control). Losartan 76-84 transforming growth factor, beta 1 Rattus norvegicus 336-346 9355076-4 1997 After subtotal renal ablation, rats fed a 40% protein diet and treated with losartan not only had a reduction in systolic BP (96 +/- 8 versus 130 +/- 8 mmHg, P < 0.05, losartan versus control) and urinary protein excretion (4 +/- 5 versus 23 +/- 20 g/d, P < 0.05, losartan versus control), but also exhibited a reduction in renal TGF-beta 1 mRNA (194 +/- 64 versus 411 +/- 101 optical density units, P < 0.05, losartan versus control) and TGF-beta 1 protein levels (9.8 +/- 2.5 versus 18.6 +/- 5.8 ng/g of renal tissue, P < 0.05, losartan versus control). Losartan 76-84 transforming growth factor, beta 1 Rattus norvegicus 448-458 9236148-10 1997 The AT1 receptor antagonist Losartan (10(-7) m) greatly attenuated Ang II-stimulated TGF-B1 secretion and decreased TGF-beta1 immunostaining in VIC. Losartan 28-36 transforming growth factor, beta 1 Rattus norvegicus 116-125 8762077-12 1996 Losartan significantly decreased mRNA levels for skeletal alpha-actin, ANP, TGF-beta 1 and collagen types I, III and IV and increased alpha-MHC mRNA in the left ventricle of SHRSP. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 76-86 8760166-5 1996 Renal transforming growth factor-beta 1 (TGF-beta 1) mRNA levels were increased threefold (P < 0.05) in RRM, RRM+ ramipril, and RRM+ losartan vs. control. Losartan 136-144 transforming growth factor, beta 1 Rattus norvegicus 6-39 8760166-5 1996 Renal transforming growth factor-beta 1 (TGF-beta 1) mRNA levels were increased threefold (P < 0.05) in RRM, RRM+ ramipril, and RRM+ losartan vs. control. Losartan 136-144 transforming growth factor, beta 1 Rattus norvegicus 41-51 33771655-8 2021 Immunohistochemistry analyses showed that TA, losartan, and TA-losartan combination downregulated the AT1R, Col IV, and TGF-beta1 expression and distribution in diabetic rat kidneys. Losartan 63-71 transforming growth factor, beta 1 Rattus norvegicus 120-129 8569085-8 1995 The increase in TGF-beta immunoreactivity and mRNA levels in aUUO and cUUO was almost totally abolished by pretreatment with losartan. Losartan 125-133 transforming growth factor, beta 1 Rattus norvegicus 16-24 7611452-7 1995 In contrast, losartan reduced TGF-beta 1 expression by 34% in obstructed kidneys but did not affect TGF-beta 1 in intact kidneys. Losartan 13-21 transforming growth factor, beta 1 Rattus norvegicus 30-40 33771655-8 2021 Immunohistochemistry analyses showed that TA, losartan, and TA-losartan combination downregulated the AT1R, Col IV, and TGF-beta1 expression and distribution in diabetic rat kidneys. Losartan 46-54 transforming growth factor, beta 1 Rattus norvegicus 120-129 34622460-10 2022 CT extract or losartan suppressed the overexpression of Ang II receptor subtype I (AT1 -R) and transforming growth factor-beta1 (TGF-beta1) in 2 K-1C rats. Losartan 14-22 transforming growth factor, beta 1 Rattus norvegicus 129-138 33606304-11 2021 CONCLUSION: Losartan might prevent NPB fibrosis by stopping the upregulated signaling of Ang II/AT1/TGFbeta1 and consequently may reduce kidney damage from occurring. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 100-108 34522623-6 2021 Losartan rescued arterial molecular alterations caused by HCB (i.e. an increase in TGF-beta1 and AT1 expression and a decrease in eNOS expression and nitrite levels) and reduced hydrogen sulfide plasma concentration. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 83-92 30021416-17 2019 CONCLUSION: Losartan might prevent axonal sprouting after hearing loss by blocking TGF-beta signaling thereby preventing maladaptive auditory-somatosensory plasticity. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 83-91 30360036-0 2019 Changes of Bax, Bcl-2, CCR-2, MCP-1, and TGF-beta1 genes in the left ventricle of spontaneously hypertensive rat after losartan treatment. Losartan 119-127 transforming growth factor, beta 1 Rattus norvegicus 41-50 30360036-7 2019 Expression of Bax, CCR-2, MCP-1, TGF-beta1, and connexin 43 proteins and kallikrein mRNA was significantly decreased after losartan treatment at week 5. Losartan 123-131 transforming growth factor, beta 1 Rattus norvegicus 33-42 30360036-10 2019 CONCLUSION: Losartan treatment reduced expression of Bax, CCR-2, MCP-1, TGF-beta1, PERK, and connexin 43 proteins, and kallikrein mRNA in SHRs, along with decreased inflammation and apoptosis. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 72-81 29849726-10 2018 In addition, western blot showed that the expression of alpha-SMA, TGF-beta, renin, and AT1 proteins was significantly decreased after receiving Qidan Dihuang decoction and losartan. Losartan 173-181 transforming growth factor, beta 1 Rattus norvegicus 67-75 30116202-4 2018 NX rats presented hypertension that was blunted by both losartan and propranolol, however, only losartan was able to reduce the expression levels of fibronectin FSP1 and TGF-beta in the remnant kidney. Losartan 96-104 transforming growth factor, beta 1 Rattus norvegicus 170-178 29056916-9 2017 Meanwhile, HRP enhanced losartan"s anti-fibrotic effects through further inhibiting phosphorylation of ERK1/2 and TGF-beta1 expression. Losartan 24-32 transforming growth factor, beta 1 Rattus norvegicus 114-123 29436789-4 2018 This study was aimed to explore the hypothesis that administration of Losartan-angiotensin II receptor antagonist increases cardiac chronotropic response to isoproterenol in cirrhotic rats; and if so, whether this is associated with altered cardiac TGF-beta receptor expression. Losartan 70-78 transforming growth factor, beta 1 Rattus norvegicus 249-257 29436789-13 2018 TGF-beta expression is markedly increased in cirrhotic rats which are significantly decreased in atria following administration of losartan. Losartan 131-139 transforming growth factor, beta 1 Rattus norvegicus 0-8 29436789-15 2018 We conclude that cirrhosis in rats is associated with altered expression of TGF-beta in the atrium which losartan can ameliorate it. Losartan 105-113 transforming growth factor, beta 1 Rattus norvegicus 76-84 29404501-6 2017 In PS-administered OLETF rats, INT747 and losartan had potent inhibitory effects on hepatic fibrogenesis with suppression of hepatic stellate cell (HSC) activation and expression of transforming growth factor beta1 and toll-like receptor 4. Losartan 42-50 transforming growth factor, beta 1 Rattus norvegicus 182-239 26175230-10 2015 A significant decrease in TGF-beta was found in the losartan and co-treated groups but not in the atorvastatin group. Losartan 52-60 transforming growth factor, beta 1 Rattus norvegicus 26-34 27176484-0 2016 Losartan Attenuates Myocardial Endothelial-To-Mesenchymal Transition in Spontaneous Hypertensive Rats via Inhibiting TGF-beta/Smad Signaling. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 117-125 27176484-12 2016 TGF-beta/Smad signaling was activated in SHRs and suppressed by Losartan or Prazosin treatment. Losartan 64-72 transforming growth factor, beta 1 Rattus norvegicus 0-8 27176484-13 2016 Losartan exhibited more efficiently than Prazosin in inhibiting TGF-beta/Smad signaling activation, EndMT and myocardial fibrosis. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 64-72 27176484-14 2016 CONCLUSION: These results showed that EndMT played an important role in promoting hypertensive cardiac fibrosis, and that losartan could suppress cardiac fibrosis through the inhibition of EndMT via classical TGF-beta/Smad pathway. Losartan 122-130 transforming growth factor, beta 1 Rattus norvegicus 209-217 24591528-6 2015 Losartan reduced TGF-beta1 in the tubules, but not in the glomeruli. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 17-26 25882007-13 2015 Moreover, losartan significantly attenuated the expression of TGF-beta1 and EMT of NRK-52E cells treated under hyperglycemic condition. Losartan 10-18 transforming growth factor, beta 1 Rattus norvegicus 62-71 22288068-11 2012 RESULTS: Twenty-one days after induction, losartan significantly improved the macro- and microscopic scores of fibrosis in the colonic wall and reduced TGF-b1 concentration. Losartan 42-50 transforming growth factor, beta 1 Rattus norvegicus 152-158 22989552-10 2013 Tissue TGF-B1 levels were significantly lower in Spironolactone and Losartan groups than in the control group only on day 3 (P = 0039). Losartan 68-76 transforming growth factor, beta 1 Rattus norvegicus 7-13 22989552-11 2013 Serum TGF-B1 levels in Losartan groups were significantly different from those of control and Spironolactone groups only on day 1 (P < 0.05). Losartan 23-31 transforming growth factor, beta 1 Rattus norvegicus 6-12 23243430-5 2012 Sal B and losartan also inhibited Ang II-stimulated HSC activation including cell proliferation and expression of type I collagen I (Col-I) and alpha-smooth muscle actin (alpha-SMA) production in vitro, reduced the gene expression of transforming growth factor beta (TGF-beta), and downregulated AT1R expression and ERK and c-Jun phosphorylation. Losartan 10-18 transforming growth factor, beta 1 Rattus norvegicus 267-275 25755735-7 2015 RESULTS: Compared with DCM rats, the quantity of p-JAK2 and p-STAT3 in myocardium of rats treated with losartan was lower, the expression of TGF-beta1 was down-regulate, the content of collagen in myocardium decreased, LVSP and +- dp/dt increased, LVEDP decreased, the level of myocardial fibrosis reduced, and heart function improved evidently. Losartan 103-111 transforming growth factor, beta 1 Rattus norvegicus 141-150 25755735-8 2015 CONCLUSION: Losartan has a protective effect on heart function against myocardial interstitial fibrosis of DCM by inhibiting JAK/STAT signaling pathway and lowering the expression of TGF-beta1. Losartan 12-20 transforming growth factor, beta 1 Rattus norvegicus 183-192 22483258-2 2013 We hypothesized that the AT1R antagonist losartan or the renin inhibitor aliskiren, given at doses allowing similar antihypertensive effects, could prevent in vivo vascular MMPs upregulation and remodeling, and collagen/elastin deposition found in 2K1C hypertension by preventing the activation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and transforming growth factor-beta1 (TGF-beta1). Losartan 41-49 transforming growth factor, beta 1 Rattus norvegicus 354-386 22483258-2 2013 We hypothesized that the AT1R antagonist losartan or the renin inhibitor aliskiren, given at doses allowing similar antihypertensive effects, could prevent in vivo vascular MMPs upregulation and remodeling, and collagen/elastin deposition found in 2K1C hypertension by preventing the activation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and transforming growth factor-beta1 (TGF-beta1). Losartan 41-49 transforming growth factor, beta 1 Rattus norvegicus 388-397 22483258-7 2013 Losartan alone or combined with aliskiren, but not aliskiren alone, abolished 2K1C-induced aortic hypertrophy and hyperplasia, and prevented the increases in aortic collagen/elastin content, MMP-2 levels, gelatinolytic activity, and expression of phospho-ERK 1/2 and TGF-beta1. Losartan 0-8 transforming growth factor, beta 1 Rattus norvegicus 267-276 23600142-9 2013 Meanwhile, treatment of losartan also significantly decreased expression of TGF-beta1 and increased expressions of PRCP, plasma kallikrein and tissue kallikrein. Losartan 24-32 transforming growth factor, beta 1 Rattus norvegicus 76-85 23600142-10 2013 The protective effects of losartan on the kidney of 2K1C hypertensive rats are activation of the axis of PRCP-kallikrein and reducing the expression of TGF-beta1. Losartan 26-34 transforming growth factor, beta 1 Rattus norvegicus 152-161 22587908-10 2012 Additionally, losartan prevented the profibrogenic response, decreasing Ang II, TGF-beta(1) and alpha-SMA levels and normalizing AQP-2 expression in the HS-L group. Losartan 14-22 transforming growth factor, beta 1 Rattus norvegicus 80-91 22288068-12 2012 CONCLUSIONS: Prophylactic oral administration of losartan reduces the colorectal fibrosis complicating the TNBS-induced chronic colitis, an effect that appears to be mediated by a downregulation of TGF-b1 expression. Losartan 49-57 transforming growth factor, beta 1 Rattus norvegicus 198-204 21868333-7 2011 CONCLUSION: High-dose losartan can effectively control blood pressure, reduce renal damage and fibrosis, and inhibit MCP1 and TGF-beta(1) expression in rats with UUO, and at a very high dose, losartan can more effectively reduce 24-h Upro than the high-dose group. Losartan 22-30 transforming growth factor, beta 1 Rattus norvegicus 126-137 21868333-1 2011 OBJECTIVE: To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-beta(1) (TGF-beta(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis. Losartan 40-48 transforming growth factor, beta 1 Rattus norvegicus 116-150 21868333-1 2011 OBJECTIVE: To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-beta(1) (TGF-beta(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis. Losartan 40-48 transforming growth factor, beta 1 Rattus norvegicus 152-163 20590668-11 2010 Pretreatment of cells for 15 min with the AT1 receptor antagonist losartan (10(-5) mol/L) attenuated high glucose-induced increases in TGF-beta1 and ERK1/2 phosphorylation and reduced EMT, as well as the consequent synthesis of fibronectin and MMP-9. Losartan 66-74 transforming growth factor, beta 1 Rattus norvegicus 135-144